The spray is available in 100mcg through 1600mcg doses and intended for cancer patients ages 18 years and older who are tolerant to opioid therapy for underlying persistent cancer pain.
Subsys is a sublingual spray formulation of fentanyl in a single unit-dose delivery device that disperses a fine mist over a broad area. In clinical trials, it reached the primary endpoint of summed pain intensity differences at 30 minutes post-treatment.
Related Articles on Pain Management:
Interventional Pain Management Physician Dr. John Hume Joins Houston’s KSF Orthopaedic Center
Tennessee Pain Bill Faces Opposition from Lawmakers, Physicians
Editorial: Kentucky Medical Association President Opposes Current Pain Clinic Legislation
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
